WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 248 participants.

Also called NCT03302494

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 248 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03302494
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03302494. Randomized; single masking; primary purpose prevention. Start 2017-12-27 (actual); primary completion 2023-12-21 (actual). Results posted on 2025-03-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2
Acronym
WAVECREST2
Condition
Stroke
Intervention (Device)
Coherex WaveCrest® Left Atrial Appendage Occlusion System
Intervention (Device)
Watchman® LAA Closure Device
Lead sponsor
Coherex Medical (class: industry)
Collaborator
Biosense Webster, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03302494
Content hash
deddd04bb4e9000ccc4130a3cb78250c1507ee5732f044a038a4e01f8281698c